Thrombosis
News
COVID-19–associated coagulopathy
Early recognition and anticoagulation is imperative to improve clinical outcomes in COVID-19–associated coagulopathies.
Conference Coverage
AUGUSTUS: After ACS or PCI, aspirin gives AFib patients scant benefit
Adding aspirin to an anticoagulant and P2Y12 inhibitor showed no net benefit, even acutely, suggesting need to target aspirin to highly selected...
From the Journals
ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients
News
Mislabeled clopidogrel lot recalled, may contain simvastatin
Conference Coverage
PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis
Conference Coverage
TWILIGHT-COMPLEX: Tap ticagrelor monotherapy early after complex PCI
“We found that the aspirin just doesn’t add that much, even in complex patients – just bleeding complications, for the most part.”
Conference Coverage
National Watchman registry reports impressive procedural safety
In-hospital stroke rate was just 0.17%, even though the registry patients were slightly older and sicker than those in clinical trials.
Conference Coverage
CARAVAGGIO expands DOAC pool in cancer-related VTE
Conference Coverage
TAILOR-PCI: Clopidogrel genotyping trial narrowly misses endpoint
The trial missed its ambitious primary endpoint of a 50% reduction in cardiovascular events, but experts felt that it still should change practice...
Conference Coverage
Rivaroxaban plus aspirin safely benefits PAD patients after limb revascularization
Conference Coverage
Anticoagulants may have advantage over aspirin for low-risk TAVR
NATIONAL HARBOR, MD. – Anticoagulant therapy is found superior to antiplatelet therapy for preventing leaflet thrombosis after TAVR.